Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer

July 30, 2019

Management of Metastatic Triple Negative Disease
Triple-negative breast cancer is an aggressive subtype that is associated with poor outcomes. Staying up-to-date on current and emerging treatment options is important to integrate new evidence-based data into their clinical practice and optimize patient outcomes. 

Genetics and molecular subtyping has helped provide additional systemic targeted therapy options for metastatic TNBC. In those in those with germline BRCA 1/2 mutations, platinum agents and PARP inhibitors have shown efficacy. However, the platinum agents have not been compared head-to-head with the PARP inhibitors. Most recently, a phase III trial showed efficacy of the PD-L1 inhibitor, atezolizumab and nab-paclitaxel as first-line therapy in patients with metastatic triple-negative breast cancer.  The treatment decision-making process and selecting optimal therapies should involve a clear understanding of available options, the benefits and risks associated, and ability to communicate this with the patients.

Target Audience

This program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe factors that help with optimal systemic treatment decisions for patients with metastatic triple negative breast cancer.
  • List the currently available therapeutic approaches for triple negative metastatic breast cancer.
  • Describe the potential adverse effects associated with the recently approved systemic therapies for metastatic triple negative breast cancer and outline strategies to manage them.
Additional information
Supporters: 

This activity is supported by an educational grant from:

  • AstraZeneca
  • Celgene Corporation
  • Clovis Oncology, Inc.
  • Eisai
  • Genomic Health, Inc.
  • Lilly
  • Novartis
  • Sanofi Genzyme
  • Taiho Oncology, Inc
  • TESARO

This activity is supported by an independent medical education grant from:

  • Advanced Accelerator Applications, a Novartis company
  • Bristol-Myers Squibb
  • Pharmacyclics LLC and Janssen

This activity is supported by an independent educational grant from:

  • Astellas and Pfizer, Inc.
  • Merck  & Co., Inc.

This activity is supported by a medical education grant from Exelixis, Inc.

(supporter list last updated on May 13, 2019)

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
05/23/2019
Course expires: 
10/18/2019
Event starts: 
07/30/2019 - 1:00pm
Event ends: 
07/30/2019 - 2:00pm
Cost:
$0.00

Melinda L. Telli, MD
Stanford Cancer Institute

Jessica Foran, MSN, WHNP-BC, ANP-BC
Stanford Cancer Institute

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Full disclosure of faculty relationships will be made prior to the activity.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-19-063-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program. 

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Accreditation Period

Course opens: 
05/23/2019
Course expires: 
10/18/2019

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

This webinar will be presented live one time only on Tuesday, July 30, 2019, from 1:00 - 2:00 PM Eastern Daylight Time (EDT) (UTC -4).  To adjust for other time zones, click here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing